Ultomiris

Ultomiris (ravulizumab) is a prescription medication used for certain blood disorders. It belongs to the class of C5 complement inhibitors. This overview covers key details for informed use.

Ravulizumab is primarily used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). These conditions involve abnormal breakdown of red blood cells or blood clots in small vessels. The medication helps reduce the need for blood transfusions in PNH and improves kidney function in aHUS. It is administered by healthcare professionals.

Ravulizumab works by targeting a specific part of the immune system to reduce harmful activity. Patients may experience improved energy levels and reduced symptoms like fatigue or shortness of breath. Regular monitoring is required to assess response and adjust treatment as needed.

This medication should only be handled and administered by trained healthcare providers. Patients must inform their doctor about all current medications and medical conditions before starting treatment. Regular blood tests are necessary to monitor effectiveness and safety. Avoid sudden changes in treatment without medical advice.

Ravulizumab may interact with other drugs that affect the immune system or blood clotting. Live vaccines should be avoided during treatment. Patients should discuss all medications, including over-the-counter and supplements, with their healthcare provider. Alcohol use may need to be limited based on individual health conditions.